Importantly, the precise lifetime BC risk thresholds at which RRM becomes cost-effective remain undetermined.18 Newer moderate penetrance genes with established BC risks (eg, CHEK2/ATM/RAD51C/RAD51D)19,20 are now being included in genetic testing panels. Here, CHEK2 is linked to breast cancer.